Status of Bi- and multi-nuclear platinum anticancer drug development

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 4, 2010, Pages 272-282

  Zhang, Jinchao ^a   Wang, Liwei ^a   Xing, Zhiyong ^a   Liu, Dandan ^a   Sun, Jing ^a   Li, Xiaoliu ^a   Zhang, Ying ^b  

^a HEBEI UNIVERSITY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Anticancer; Binuclear platinum(II) complexes; Multinuclear platinum(II) complexes; Platinum(II) complexes

Indexed keywords

CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; EPTAPLATIN; LOBAPLATIN; NEDAPLATIN; OXALIPLATIN; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; DNA ADDUCT; DRUG DNA INTERACTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW;

EID: 77951656573     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010791162270     Document Type: Review

References (63)

1. Boulikas, T.; Vougiouka, M. Cisplatin and platinum drugs at the molecular level. Oncol. Rep., 2003, 10, 1663-1682.
2. Ho, Y.P.; Au-Yeung, S.C.F.; To, K.K.W. Platinum-based anticancer agents: Innovative design strategies and biological perspectives. Med. Res. Rev., 2003, 23, 633-655.
3. Kostova, I. Platinum complexes as anticancer agents. Recent Pat. Anticancer Drug Discov., 2006, 1(1), 1-22.
4. Jakupec, M.A.; Galanski, M.; Keppler, B.K. Tumour-inhibiting platinum complexes-state of the art and future perspectives. Rev. Physiol. Biochem. Pharmacol., 2003, 146, 1-53.
5. Cleare, M.J.; Hoeschele, J.D. Antitumor platinum compounds. Relation between structure and activity. Plat. Met. Rev., 1973a, 17, 2-13.
6. Wong, E.; Giandomenico, C.M. Current status of platinum-based antitumor drugs. Chem. Rev., 1999, 99, 2451-2466.
7. Wheate, N.J.; Collins, J.G. Multi-nuclear platinum complexes as anti-cancer agents. Coord. Chem. Rev., 2003, 241, 133-145.
8. Wheate, N.J.; Collins, J.G. Multi-nuclear platinum drugs: a new paradigm in chemotherapy. Curr. Med. Chem. - Anti-Cancer Agents, 2005, 5(3), 267-279. (Pubitemid 40645594)
9. Broomhead J.A.; Rendina, L.M.; Sterns, M. Dinuclear complexes of platinum with the 4,4′-dipyrazolylmethane ligand. Synthesis, characterization, and x-ray crystal structure of .gamma.-bis(4,4′-dipyrazolylmethane-N, N′)bis[dichloroplatinum(II)]-N,Ndimethylformamide (1/2) and related complexes. Inorg. Chem., 1991, 31(10), 1880-1889.
10. Broomhead, J.A.; Rendina, L.M.; Webster, L.K. Dinuclear complexes of platinum having anticancer properties. DNA-binding studies and biological activity of bis(4,4'-dipyrazolylmethane-N,N′)-bis[dichloroplatinum(II) and related complexes. J. Inorg. Biochem., 1993, 49(3), 221-234. (Pubitemid 23043419)
11. Broomhead, J.A.; Lynch, M.J. The synthesis and characterization of dinuclear platinum complexes bridged by the 4,4′-dipyrazolylmethane ligand. Inorg. Chim. Acta, 1995, 240(1-2), 13-17.
12. Farrell, N.Y.; Qu, L.; Feng, B.; Van H. Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues. Biochemistry, 1990, 29, 9522-9531.
13. 2 units linked in a linear fashion. Inorg. Chem., 1993, 32(11), 2591-2593.
14. 2 units. Synthesis and initial DNA-binding studies. J. Am. Chem. Soc., 1988, 110, 5018-5019.
15. Farrell, N.; Qu, Y.; Hacker, M.P. Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. J. Med. Chem., 1990, 33(8), 2179-2184.
16. Qu, Y.; Farrell, N. The product of the reaction of trans- diamminedichloroplatinum(II) with diamines is dependent on chain length. Example of a bridging ethylenediamine and formation of a novel trans-chelated structure with 1,5-pentanediamine. Inorg. Chem., 1992, 31(5), 930-932.
17. Qu, Y.; Farrell, N. Interaction of bis(platinum) complexes with the mononucleotide 5′-guanosine monophosphate. Effect of diamine linker and the nature of the bis(platinum) complex on product formation. J. Am. Chem. Soc., 1991, 113(13), 4851-4857.
18. Qu, Y.; Rauter, H.; Soares Fontes, A.P.; Bandarage, R.; Kelland, L.R.; Farrell, N. Synthesis, characterization, and cytotoxicity of trifunctional dinuclear platinum complexes: Comparison of effects of geometry and polyfunctionality on biological activity. J. Med. Chem., 2000, 43(16), 3189-3192.
19. Jansen, B.A.J.; van der Zwan, J.; den Dulk, H.; Brouwer, J.; Reedijk, J. Dinuclear alkyldiamine platinum antitumor compounds: A structure-activity relationship study. J. Med. Chem., 2001, 44(2), 245-249. (Pubitemid 32096669)
20. Jansen, B.A.J.; Brouwer, J.; Reedijk, J. Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. J. Inorg. Biochem., 2002, 89(3-4), 197-202. (Pubitemid 34327260)
21. Qu, Y.; Fitzgerald, J.A.; Rauter, H.; Farrell, N. Approaches to selective DNA binding in polyfunctional dinuclear platinum chemistry. The synthesis of a trifunctional compound and its interaction with the mononucleotide 5′-guanosine monophosphate. Inorg. Chem., 2001, 40(24), 6324-6327. (Pubitemid 33091560)
22. Wheate, N.J.; Cullinane, C.; Webster, L.K.; Collins, J.G. Synthesis, cytotoxicity, cell uptake and DNA interstrand cross-linking of 4,4′-dipyrazolylmethane-linked multinuclear platinum anti-cancer complexes. Anti-Cancer Drug Des., 2001, 16 , 91-98.
23. Komeda, S.; Lutz, M.; Spek, A.L.; Chikuma, M.; Reedijk, J. New antitumor-active azole-bridged dinuclear platinum(II) complexes: Synthesis, characterization, crystal structures, and cytotoxic studies. J. Inorg. Chem., 2000, 39(19), 4230-4236.
24. Komeda, S.; Lutz, M.; Spek, A.L.; Yamanaka,Y.; Sato,T.; Chikuma, M.; Reedijk, J. A novel isomerization on interaction of antitumor-active azole-bridged dinuclear platinum(II) complexes with 9-ethylguanine. Platinum(II) atom migration from N2 to N3 on 1,2,3-triazole. J. Am. Chem. Soc., 2002, 124(17), 4738-4746. (Pubitemid 34465012)
25. 2. Inorg. Chem., 2002, 41(17), 4539-4547.
26. Liang, X.; Weishaupl, M.; Parkinson, J.A.; Parsons, S.; McGregor, P.A.; Sadler, P.J. Selective recognition of configurational substates of zinc cyclam by carboxylates: Implications for the design and mechanism of action of anti-HIV agents. Chem. Eur. J., 2003, 9(19), 4709-4717.
27. Liang, X.; Sadler, P.J. Cyclam complexes and their applications in medicine. Chem. Soc. Rev., 2004, 33, 246-266.
28. Hunter, T.M.; McNae, I.W.; Liang, X.; Bella, J.; Parsons, S.; Walkinshaw, M.D.; Sadler, P.J. Protein recognition of macrocycles: Binding of anti-HIV metallocyclams to lysozyme. Proc. Natl. Acad. Sci. USA, 2005, 102, 2288-2292.
29. Valks, G.C.; McRobbie, G.; Lewis, E.A.; Hubin, T.J.; Hunter, T.M.; Sadler, P.J.; Pannecouque, C.; De Clercq, E.; Archibald, S.J. Configurationally restricted bismacrocyclic CXCR4 receptor antagonists. J. Med. Chem., 2006, 49(21), 6162-6165. (Pubitemid 44595193)
30. Xu, Z.H.; Zhang, Y.M; Xue, Z.Q.; Yang, X.L.; Wu, Z.Y.; Guo, Z.J. DNA-binding property and antitumor activity of a cyclam bridged dinuclear platinum(II) complex. Inorg. Chim. Acta, 2009, 362(7), 2347-2352.
31. Kalayda, G.V.; Komeda, S.J.; Ikeda, K.; Sato, T.; Chikuma, M.; Reedijk, J. Synthesis, structure, and biological activity of new azine-bridged dinuclear platinum(II) complexes - a new class of anticancer compounds. Eur. J. Inorg. Chem. 2003, 24, 4347-4355.
32. + units bridged by 4,4′-dipyridyl selenides or sulfides. Anti-Cancer Drug Des., 1998, 13(7), 769-777.
33. 2 (L = Monofunctional thiourea derivative; L-L = Bifunctional thiourea derivative) in relation to their cytotoxicity. Inorg. Chem., 1998, 37(4), 717-723.
34. Farrell, N.; Qu, Y.; Kasparkova, J.; Brabec, V.; Valsecchi, M.; Menta, E.; Di Domenico, R.; Da Re, G.; Lotto, A.; Spinelli, S. A new treatment approach for malignant brain tumors. Proc. Am. Assoc. Cancer Res., 1997, 38, 2077-2080.
35. Rauter, H.; Di Domenico, R.; Menta, E.; Oliva, A.; Qu, Y.; Farrell, N. Selective platination of biologically relevant polyamines. Linear coordinating spermidine and spermine as amplifying linkers in dinuclear platinum complexes. Inorg. Chem., 1997, 36(18), 3919-3927. (Pubitemid 127515220)
36. Di Blasi, P.; Bernareggi, A.; Beggiolin, G.; Piazzoni, L.; Menta, E.; Formento, M. Cytotoxicity, cellular uptake and DNA binding of noval trinuclear platinum complex BBR 3464 in sensitive and cisplatin resistant murine leukemia cells. Anti-Cancer Res., 1998, 18, 3113-3118.
37. Sharp, S.Y.; Kelland, L.R. BBR-3464. Curr. Opin. Oncol. Endocr. Metab. Invest. Drugs, 2000, 2, 353-360.
38. Hegmans, A.; Qu, Y.; Kelland, L.R.; Roberts, J.D.; Farrell, N. Novel approaches to polynuclear platinum pro-drugs. Selective release of cytotoxic platinum-spermidine species through hydrolytic cleavage of carbamates. Inorg. Chem., 2001, 40(24), 6108-6114. (Pubitemid 33091533)
39. Kelland, L.R.; Sharp, S.Y. Platinum compounds in cancer therapy. Curr. Opin. Oncol. Endocr. Metab. Invest. Drugs, 1999, 1, 380-385.
40. Orlandi, L.; Colella, G.; Bearzatto, A.; Abolafio, G.; Manzotti, L.; Daidone, M.G.; Zaffaroni, N. Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: interference with cell cycle progression and induction of apoptosis. Eur. J. Cancer, 2001, 37(5), 649-659. (Pubitemid 32266082)
41. Collela, G.; Pennati, M.; Bearzatto, A.; Leone, R.; Colangelo, D.; Manzotti, C.; Daidone, M.G.; Zaffaroni, N. Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: Cytotoxicity and induction and gene-specific repair of DNA lesions Br. J. Cancer, 2001, 84, 1387-1390. (Pubitemid 32522109)
42. Adoracion, G.; Quiroga a, Perez, J.M.; Lopez-Solera, I.; Montero, E.I.; Masaguer, J.R.; Alonso, C.; Navarro-Ranninger, C. Binuclear chloro-bridged palladated and platinated complexes derived from p-isopropylbenzaldehyde thiosemicarbazone with cytotoxicity against cisplatin resistant tumor cell lines. J. Inorg. Biochem., 1998, 69(4), 275-281.
43. Zhang, J.C.; Liu, L.; Gong, Y.Q.; Zheng, X.M.; Yang, M.S.; Cui, J.R.; Shen, S.G.. Synthesis, characterization and antitumor activity of new type binuclear platinum(II) complexes. Eur. J. Med.Chem., 2009, 44(5), 2322-2327.
44. Zhang, J.C.; Li, Y.P,; Sun, J.; Li, W.X.; Gong, Y.Q.; Zheng, X.M.; Cui, J.R.; Wang, R.Q.; Wu, J. Synthesis, cytotoxicity and DNAbinding levels of new type binuclear platinum(II) complexes. Eur. J. Med. Chem., 2009, 44(11), 4772-4777.
45. Jin, V.X.; Ranford, J.D. Complexes of platinum(II) or palladium(II) with 1,10-phenanthroline and amino acids. Inorg. Chim. Acta, 2000, 304(1), 38-44.
46. Temple, M.D.; McFadyen, W.D.; Holmes, R.J.; Denny, W.A.; Murray, V. Interaction of cisplatin and DNA-targeted 9-aminoacridine platinum complexes with DNA. Biochemistry, 2000, 39(18), 5593-5599. (Pubitemid 30257102)
47. Holmes, R.J.; McKeage, M.J.; Murray, V.; Denny, W.A.; McFadyen, W.D. cis-Dichloroplatinum(II) complexes tethered to 9-aminoacridine-4-carboxamides: Synthesis and action in resistant cell lines in vitro. J. Inorg. Biochem., 2001, 85(2-3), 209-217.
48. Cai, L.; Keunpoong, L.; Ren, S.; Cadena, R.S.; Beck, W.T. Synthesis and in vitro antitumor activity of oligonucleotide-tethered and related platinum complexes. J. Med.Chem., 2001, 44(18), 2959-2965. (Pubitemid 32884152)
49. Locher, G.L. Biologic effects and therapeutic possibilities of neutrons. Am. J. Roentgenol. Radium Ther., 1936, 36, 1-13.
50. Woodhouse, S.L.; Rendina, L.M. Synthesis and DNA-binding properties of dinuclear platinum(II)-amine complexes of 1,7-dicarba-closo-dodecaborane(12). Chem. Comm., 2001, 23, 2464-2465. (Pubitemid 33124087)
51. Todd, J.A.; Rendina, L.M. Synthesis and DNA-binding properties of cationic 2,2':6, 2'-terpyridineplatinum(II) complexes containing 1,2- and 1,7-dicarba-closo-dodecaborane(12). Inorg. Chem., 2002, 41(13), 3331-3333.
52. Todd, J.A.; Rendina, L.M. The first examples of platinum(II)-amine complexes containing 1,2-dicarba-closo-dodecaborane(12). Inorg. Chem. Comm., 2004, 7(2), 289-291.
53. Woodhouse, S.L.; Rendina, L.M. Multinuclear platinum(II)-amine complexes containing bis(aminopropyl)dicarba-closododecaborane(12) ligands. Dalton Trans., 2004, 21, 3669-3677.
54. Kalayda, G.V.; Jansen, B.A. J.; Wielaard, P.; Tanke, H.J.; Reedijk, J. Dinuclear platinum anticancer complexes with fluorescent N, N′- bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles. J. Biol. Inorg. Chem., 2005, 10(3), 305-315. (Pubitemid 40768095)
55. Pratesi, G.; Perego, P.; Polizzi, D.; Righetti, S.C.; Supino, R.; Caserini, C.; Giuliani, C. F.C.; Pezzoni, G.; Tognella, S.; Spinelli, S.; Farrell, N.; Zunino, F. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br. J. Cancer, 1999, 80, 1912-1919. (Pubitemid 29391274)
56. Roberts, J.D.; Peroutka, J.; Beggiolin, G.; Manzotti, C.; Piazzoni, L.; Farrell, N. Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. J. Inorg. Biochem., 1999, 77(1-2), 47-50. (Pubitemid 30089081)
57. Roberts, J.D.; Peroutka, J.; Farrell, N. Cellular pharmacology of polynuclear platinum anti-cancer agents. J. Inorg. Biochem., 1999, 77(1-2), 51-57. (Pubitemid 30089082)
58. Kelland, L.R.; Farrell, N.; Eds. Platinum Based Drugs in Cancer Therapy, Humana Press: New Jersey, 2000.
59. Kasparkova, J.; Vrana, O.; Farrell, N.; Brabec, V. Effect of the geometry of the central coordination sphere in antitumor trinuclear platinum complexes on DNA binding. J. Inorg. Biochem., 2004, 98(10), 1560-1569. (Pubitemid 39349181)
60. Jansen, B.A.J.; van der Zwan, J.; den Dulk, H.; Brouwer, J.; Reedijk, J. Dinuclear alkyldiamine platinum antitumor compounds: A structure-activity relationship study J. Med. Chem., 2001, 44(2), 245-249. (Pubitemid 32096669)
61. Jansen, B.A.J.; van der Zwan, J.; Reedijk, J.; den Dulk, H.; Brouwer, J. A. Tetranuclear platinum compound designed to overcome cisplatin resistance. Eur. J. Inorg. Chem., 1999, 9, 1429-1433.
62. Menta, E.; Farrell, N.; Valsecchi, M.; Conti, M.; Piazzoni, L.; Randisi, E.; Manzotti, L.; Pezzoni, G.; Spinelli, S. Antitumor evaluation of linker-modified trinuclear platinum complexes congeners of the phase I clinical againt BBR3464. ISPCCC, Oxford, UK: P13, 1999.
63. Lippert, B.; Ed. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, Wiley-VCH: New York, 1999